menu
    • menu

    Company profile for EuMentis Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EuMentis Therapeutics Inc. is a privately held biopharmaceutical company focused on developing novel therapies to treat high value neurodevelopmental and neurodegenerative diseases. The Company’s lead program, EM-036, is a nitro-aminoadamantane N-methyl-D-aspartate (NMDA) receptor antagonist in preclinical development for the treatment of multiple CNS diseases including Alzheimer’s Disease and Autism-Spectrum Disorders...
    EuMentis Therapeutics Inc. is a privately held biopharmaceutical company focused on developing novel therapies to treat high value neurodevelopmental and neurodegenerative diseases. The Company’s lead program, EM-036, is a nitro-aminoadamantane N-methyl-D-aspartate (NMDA) receptor antagonist in preclinical development for the treatment of multiple CNS diseases including Alzheimer’s Disease and Autism-Spectrum Disorders. Preclinical data to date demonstrate significant improvement in efficacy of EM-036 over Namenda® in Alzheimer's Disease and Autism-Spectrum Disorder models with no safety issues.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EuMentis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    508 Dudley Rd # 105 Newton, MA, 02459-2809
    Telephone
    Telephone
    (617) 413-3020
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eumentistx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eumentis-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EuMentis Gets FDA Clearance for Schizophrenia IND Application
    EuMentis Gets FDA Clearance for Schizophrenia IND Application

    30 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eumentis-therapeutics-receives-us-fda-clearance-of-ind-application-for-em-221-a-novel-pde10a-inhibitor-for-schizophrenia-302517449.html

    PR NEWSWIRE
    30 Jul 2025
    Share Share
    EuMentis Announces the First Closing of a Targeted $40M Series B Financing
    EuMentis Announces the First Closing of a Targeted $40M Series B Financing

    15 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/15/2608538/0/en/EuMentis-Therapeutics-Inc-Announces-the-First-Closing-of-a-Targeted-40M-Series-B-Financing-to-Advance-Novel-Therapeutics-to-Treat-Autism-Spectrum-Disorder-Tourette-Syndrome-and-Tra.html

    GLOBENEWSWIRE
    15 Feb 2023
    Share Share
    ImmunityBio, Codagenix and EuMentis raise funds, while a biotech SPAC dissolves
    ImmunityBio, Codagenix and EuMentis raise funds, while a biotech SPAC dissolves

    15 Feb 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/immunitybio-codagenix-and-eumentis-raise-funds-while-a-biotech-spac-dissolves/

    Kyle LaHucik ENDPTS
    15 Feb 2023
    Share Share
    EuMentis Receives $3M Award from US DoD to Advance NMDA Receptor Antagonist
    EuMentis Receives $3M Award from US DoD to Advance NMDA Receptor Antagonist

    08 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/08/2603783/0/en/EuMentis-Therapeutics-Inc-Receives-3-Million-Award-from-United-States-Department-of-Defense-DoD-to-Advance-its-Novel-NMDA-Receptor-Antagonist-for-Traumatic-Brain-Injury.html

    GLOBENEWSWIRE
    08 Feb 2023
    Share Share
    Biotech receives award from DOD; Regulators accept Appili Therapeutics' NDA
    Biotech receives award from DOD; Regulators accept Appili Therapeutics' NDA

    08 Feb 2023

    // ENDPTS

    https://endpts.com/biotech-receives-award-from-dod-regulators-accept-appili-therapeutics-nda/

    ENDPTS
    08 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search